Is it Time to Update cGMPs?

Industry practice has changed radically over the past five decades. Can laws published in the 1960s still ensure pharmaceutical quality and safety today?

The biopharmaceutical industry has undergone major changes since GMPs were last updated in 1977. However, FDA says it has no plans for any major revisions of cGMPs. Industry experts argue, however, that changes are needed in Training and employee personal development, statistics and sampling, and process validation.

Read this article in BioPharm International’s September 2019 Regulatory Sourcebook.

Article Details

BioPharm International
eBook: Regulatory Sourcebook, September 2019
September 2019
Pages: 10–13

Citation

When referring to this article, please cite it as A. Shanley, “Is it Time to Update cGMPs?" BioPharm International Regulatory Sourcebook eBook (September 2019).

Articles in this issue

almost 7 years ago

Article

Global Pharmacopoeia Standards: Why Harmonization is Needed (eBook)

almost 7 years ago

Article

Why Pharmacopoeia Compliance Is Difficult (eBook)

almost 7 years ago

Article

Why Pharmacopoeia Compliance Is Necessary (eBook)

almost 7 years ago

Article

What’s New in Regulations and Compliance

almost 7 years ago

Article

Quality Culture Drives Patient Confidence in Drug Products

almost 7 years ago

Article

Biosimilar Quality Requirements

almost 7 years ago

Article

Regulatory and Standard Setting Organizations

almost 7 years ago

Article

Resources, Guidelines, and Guidance Documents

Newsletter

Stay at the forefront of biopharmaceutical innovation. Subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.